Scottish adolescents get Stelara

[Fred]

The Scottish Medicines Consortium (SMC) has completed its assessment of Stelara and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland in adolescent patients.

The advice is summarised as follows:

Quote:

---

Following an abbreviated submission ustekinumab (Stelara) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of moderate to severe plaque psoriasis in adolescent
patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant
to, other systemic therapies or phototherapies.

SMC restriction: continued treatment should be restricted to patients who achieve at least 75%
improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.

Source: scottishmedicines.org.uk